Lauren classification and individualized chemotherapy in gastric cancer (Review)
- Authors:
- Junli Ma
- Hong Shen
- Linda Kapesa
- Shan Zeng
-
Affiliations: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Key Laboratory for Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China - Published online on: March 16, 2016 https://doi.org/10.3892/ol.2016.4337
- Pages: 2959-2964
-
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guggenheim DE and Shah MA: Gastric cancer epidemiology and risk factors. J Surg Oncol. 107:230–236. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Patru CL, Surlin V, Georgescu I and Patru E: Current issues in gastric cancer epidemiology. Rev Med Chir Soc Med Nat Iasi. 117:199–204. 2013.PubMed/NCBI | |
|
Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI | |
|
Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang DS, Li YH and Xu RH: Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 11:582013. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K and Takano Y: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: An immunostaining study on the tissue microarray. J Clin Pathol. 60:273–277. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YC, Fang WL, Wang RF, Liu CA, Yang MH, Lo SS, Wu CW, Li AF, Shyr YM and Huang KH: Clinicopathological variation of lauren classification in gastric cancer. Pathol Oncol Res. 22:197–202. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hommel C, Knoedler M, Bojarski C, Schumann M, Epple HJ, Zeitz M and Daum S: Diffuse gastric cancer with peritoneal carcinomatosis can mimic Crohn's disease. Case Rep Gastroenterol. 6:695–703. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Stiekema J, Cats A, Kuijpers A, van Coevorden F, Boot H, Jansen EP, Verheij M, Ponz Balague O, Hauptmann M and van Sandick JW: Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol. 39:686–693. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kaneko S and Yoshimura T: Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989. Br J Cancer. 84:400–405. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M and Shinomura Y: Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion. 83:241–249. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fu DG: Epigenetic alterations in gastric cancer. Mol Med Rep. 12:3223–3230. 2015.(Review). PubMed/NCBI | |
|
Martínez-Madrigal F, Ortiz-Hidalgo C, Torres-Vega C, Alvarez L, Manzo-Montaño A, García-López L and Esquivel-Ayanegui F: Atypical regenerative changes, dysplasia, and carcinoma in situ in chronic gastritis associated with Helicobacter pylori. Rev Gastroenterol Mex. 65:11–17. 2000.(In Spanish). PubMed/NCBI | |
|
Kodama M, Murakami K, Okimoto T, Abe T, Nakagawa Y, Mizukami K, Uchida M, Inoue K and Fujioka T: Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion. 85:126–130. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Asaka M: Elimination of gastric cancer from Japan. Nihon Rinsho. 70:1667–1672. 2012.(In Japanese). PubMed/NCBI | |
|
Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, Oguma K, Okada H and Yamamoto K: The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 46:318–324. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vannella L, Lahner E and Annibale B: Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World J Gastroenterol. 18:1279–1285. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rokkas T, Pistiolas D, Sechopoulos P, Robotis I and Margantinis G: The long-term impact of Helicobacter pylori eradication on gastric histology: A systematic review and meta-analysis. Helicobacter. 12(Suppl 2): S32–S38. 2007. View Article : Google Scholar | |
|
Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H, et al: Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 75:39–46. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pereyra L, Gómez EJ, Mella JM, Casas G, Bugari G, Cimmino D, Pedreira S and Boerr LA: Diffuse gastric cancer associated with Ménétrier's disease. Acta Gastroenterol Latinoam. 41:142–145. 2011.(In Spanish). PubMed/NCBI | |
|
Palestro G, Pellicano R, Fronda GR, Valente G, De Giuli M, Soldati T, Pugliese A, Taraglio S, Garino M, Campra D, et al: Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol. 11:7131–7135. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nardone G, Rocco A and Malfertheiner P: Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther. 20:261–270. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida T, Kato J, Maekita T, Yamashita S, Enomoto S, Ando T, Niwa T, Deguchi H, Ueda K, Inoue I, et al: Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. Gastric Cancer. 16:488–497. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Corso G, Marrelli D and Roviello F: Familial gastric cancer: Update for practice management. Fam Cancer. 10:391–396. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oliveira C, Pinheiro H, Figueiredo J, Seruca R and Carneiro F: Familial gastric cancer: Genetic susceptibility, pathology, and implications for management. Lancet Oncol. 16:e60–e70. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vogelaar IP, van der Post RS, Bisseling TM, van Krieken JH, Ligtenberg MJ and Hoogerbrugge N: Familial gastric cancer: Detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract. 10:182012. View Article : Google Scholar : PubMed/NCBI | |
|
Carneiro F: Hereditary gastric cancer. Pathologe. 33(Suppl 2): S231–S234. 2012. View Article : Google Scholar | |
|
Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, Seruca R, Carneiro F and Sobrinho-Simöes M: E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 20:1525–1528. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kim IJ, Kang HC, Shin Y, Park HW, Jang SG, Han SY, Lim SK, Lee MR, Chang HJ, Ku JL, et al: A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum Genet. 49:591–595. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kim S, Chung JW, Jeong TD, Park YS, Lee JH, Ahn JY, Kim DH, Choi KD, Lee W, Song HJ, et al: Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. Fam Cancer. 12:503–507. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bacani JT, Soares M, Zwingerman R, di Nicola N, Senz J, Riddell R, Huntsman DG and Gallinger S: CDH1/E-cadherin germline mutations in early-onset gastric cancer. J Med Genet. 43:867–872. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A, Pascale V, Seruca R, Oliveira C and Roviello F: E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 47:631–639. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo AM, Magnani M, Toro T, Burchill T, Futschik ME, Merriman T and Guilford P: Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene. 21:8192–8195. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Liu YC, Shen CY, Wu HS, Hsieh TY, Chan DC, Chen CJ, Yu JC, Yu CP, Harn HJ, Chen PJ, et al: Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol. 12:2168–2173. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ramos-de la Medina A, More H, Medina-Franco H, Humar B, Gamboa A, Ortiz LJ, Donohue JH and Guilford P: Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer. Rev Esp Enferm Dig. 98:36–41. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hoogerbrugge N, Ligtenberg MJ, Nagengast FM, Bonenkamp JJ and van Krieken JH: Preventive resection of hereditary diffuse gastric cancer. Ned Tijdschr Geneeskd. 150:2417–2420. 2006.(In Dutch). PubMed/NCBI | |
|
Kluijt I, Sijmons RH, Hoogerbrugge N, Vasen HF and Cats A: Familial gastric cancer: Diagnosis, treatment and periodic surveillance. Ned Tijdschr Geneeskd. 155:A27312011.(In Dutch). PubMed/NCBI | |
|
Schildberg CW, Abba M, Merkel S, Agaimy A, Dimmler A, Schlabrakowski A, Croner R, Leupold JH, Hohenberger W and Allgayer H: Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations. Adv Med Sci. 59:142–146. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, An JY, Noh SH, Shin SK, Lee YC and Kim H: High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. J Gastroenterol Hepatol. 26:585–592. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, Lu J, Jin Y, Wei X, Zhang D, et al: Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 14:8232014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu ZY, Zhan WH, Li JH, He YL, Wang JP, Lan P, Peng JS and Cai SR: Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis. World J Gastroenterol. 11:3139–3143. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, Lazăr E and Vernic C: The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival. Rom J Morphol Embryol. 49:459–467. 2008.PubMed/NCBI | |
|
Stănculescu D, Mărgăritescu C, Stepan A and Mitruţ AO: E-cadherin in gastric carcinomas related to histological prognostic parameters. Rom J Morphol Embryol. 52(Suppl 3): S1107–S1112. 2011. | |
|
Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S and Karatzas G: E-cadherin expression as a differentiation marker in gastric cancer. Hepatogastroenterology. 45:2437–2442. 1998.PubMed/NCBI | |
|
Asano N, Imatani A, Watanabe T, Fushiya J, Kondo Y, Jin X, Ara N, Uno K, Iijima K, Koike T, et al: Cdx2 expression and intestinal metaplasia induced by H. pylori infection of gastric cells is regulated by NOD1-mediated innate immune responses. Cancer Res. Jan 12–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Almeida R, Almeida J, Shoshkes M, Mendes N, Mesquita P, Silva E, Van Seuningen I, Reis CA, Santos-Silva F and David L: OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol. 207:396–401. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mesquita P, Jonckheere N, Almeida R, Ducourouble MP, Serpa J, Silva E, Pigny P, Silva FS, Reis C, Silberg D, et al: Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem. 278:51549–51556. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HS, Lee JS, Freund JN, Min KW, Lee JS, Kim W, Juhng SW and Park CS: CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. J Gastroenterol Hepatol. 21:438–442. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Seno H, Oshima M, Taniguchi MA, Usami K, Ishikawa TO, Chiba T and Taketo MM: CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: Prognostic implications. Int J Oncol. 21:769–774. 2002.PubMed/NCBI | |
|
Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, Itoh M, Yamamura Y and Tatematsu M: Expression of Cdx2 and the phenotype of advanced gastric cancers: Relationship with prognosis. J Cancer Res Clin Oncol. 129:727–734. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Fan Z, Li J, Dong B and Huang X: Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: Correlation with histologic type and implications for prognosis. Clin Cancer Res. 11:6162–6170. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Fang WL, Chang SC, Lan YT, Huang KH, Chen JH, Lo SS, Hsieh MC, Li AF, Wu CW and Chiou SH: Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg. 36:2131–2138. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JY, Shin NR, Kim A, Lee HJ, Park WY, Kim JY, Lee CH, Huh GY and Park DY: Microsatellite instability status in gastric cancer: A reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J Pathol. 47:28–35. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan DD, Zhu ZX, Zhang X and Liu J: Targeted therapy for gastric cancer: Current status and future directions. Oncol Rep. 35:1245–1254. 2016.(Review). PubMed/NCBI | |
|
Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 51:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, et al: Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann Oncol. 23:2656–2662. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sornmayura P, Rerkamnuaychoke B, Jinawath A and Euanorasetr C: Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients. J Med Assoc Thai. 95:88–95. 2012.PubMed/NCBI | |
|
Ishida M, Kagawa S, Shimoyama K, Takehara K, Noma K, Tanabe S, Shirakawa Y, Tazawa H, Kobayashi H and Fujiwara T: Trastuzumab-based photoimmunotherapy integrated with viral HER2 transduction inhibits peritoneally disseminated HER2-negative cancer. Mol Cancer Ther. Feb 1–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Gagliato DM, Jardim DL, Marchesi MS and Hortobagyi GN: Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016.PubMed/NCBI | |
|
Liu W, Zhong S, Chen J and Yu Y: HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol. 46:e31–e37. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wu HM, Liu YH, Lin F, Xu FP, Luo DL, Zhang F, Zhuang HG, Luo XL, Wu WL and Lin XT: Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma. Zhonghua Bing Li Xue Za Zhi. 40:296–299. 2011.(In Chinese). PubMed/NCBI | |
|
Förster S, Gretschel S, Jöns T, Yashiro M and Kemmner W: THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling. Mod Pathol. 24:1390–1403. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MA, Lee HS, Yang HK and Kim WH: Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer. 103:1439–1446. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al: Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. Dec 22–2015.(Epub ahead of print). | |
|
He HY, Wang XF, Shen ZB, Chen WD and Sun YH: Association of transcriptional repressor Snail with Lauren classification of gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 15:852–854. 2012.(In Chinese). PubMed/NCBI | |
|
Jackson C, Mochlinski K and Cunningham D: Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy. Oncology (Williston Park). 21:1084–1087, 1090, 1096–1098, 1101. 2007.PubMed/NCBI | |
|
Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, et al: CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 104:1126–1134. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Chen JQ, Liu JL, Qin XG and Huang Y: Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: A systematic review. BMC Gastroenterol. 12:1372012. View Article : Google Scholar : PubMed/NCBI | |
|
Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi K, et al: Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist. 19:358–366. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I and Falcon S: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C and Sakata Y: Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 14:72–80. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y and Taguchi T: Paclitaxel Gastric Cancer Study Group in Japan: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 5:90–95. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kato K, Chin K, Yoshikawa T, Yamaguchi K, Tsuji Y, Esaki T, Sakai K, Kimura M, Hamaguchi T, Shimada Y, et al: Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs. 30:1621–1627. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al: JACCRO and KCSG Study Group: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START). J Cancer Res Clin Oncol. 140:319–328. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K and Araki K: Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 12:1412–1415. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S and Kaisaki S: S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis. Gastrointest Cancer Res. 5(Suppl 1): S10–S13. 2012.PubMed/NCBI | |
|
Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, Watanabe M, Kumai K and Kitajima M: Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 24:2455–2463. 2004.PubMed/NCBI |
